GRAFT VERSUS HOST DISEASE
Clinical trials for GRAFT VERSUS HOST DISEASE explained in plain language.
Never miss a new study
Get alerted when new GRAFT VERSUS HOST DISEASE trials appear
Sign up with your email to follow new studies for GRAFT VERSUS HOST DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Fetal stem cells aim to tame immune chaos
Disease control ENROLLING_BY_INVITATIONThis early-stage trial tests clonal fetal mesenchymal stem cells (cfMSCs) in 100 people with severe immune-related disorders or tissue damage. The goal is to see if the cells are safe and can reduce symptoms. Participants have no other treatment options left.
Matched conditions: GRAFT VERSUS HOST DISEASE
Phase: PHASE1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Donor stem cell transplant shows promise for tough blood cancers
Disease control OngoingThis study tests a stem cell transplant from a matched unrelated donor for people with advanced blood cancers or blood disorders. Patients get chemotherapy and radiation before the transplant to prepare their body, then take drugs to prevent the donor cells from attacking their o…
Matched conditions: GRAFT VERSUS HOST DISEASE
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New transplant method aims to reduce dangerous immune reactions
Disease control OngoingThis study tests a stem cell transplant method for people with blood cancers like leukemia or lymphoma. The approach uses chemotherapy, total body radiation, and a drug called cyclophosphamide after the transplant to prevent graft-versus-host disease, where donor cells attack the…
Matched conditions: GRAFT VERSUS HOST DISEASE
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for older blood cancer patients: lower-dose combo may reduce transplant complications
Disease control OngoingThis study tests whether a lower-dose combination of two drugs (PTCy and ruxolitinib) can prevent graft-versus-host disease (GVHD) in older adults receiving a stem cell transplant for blood cancer. About 56 participants will receive the treatment and be monitored for survival wit…
Matched conditions: GRAFT VERSUS HOST DISEASE
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New transplant method aims to reduce dangerous side effects in blood cancer patients
Disease control TerminatedThis phase II trial tests a special stem cell transplant that removes immune T-cells from the donor's blood to lower the risk of graft-versus-host disease (GVHD), a serious complication where the donor cells attack the patient's body. About 50 adults with myelodysplastic syndrome…
Matched conditions: GRAFT VERSUS HOST DISEASE
Phase: PHASE2 • Sponsor: Guenther Koehne • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug combo may shield kids from transplant complications
Disease control OngoingThis study tests whether adding the drug abatacept to standard care can prevent graft-versus-host disease (GVHD) in children receiving stem cell transplants from unrelated donors. GVHD occurs when donor cells attack the patient's body, causing serious illness. The trial will enro…
Matched conditions: GRAFT VERSUS HOST DISEASE
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Could a cancer drug shield young transplant patients from a deadly complication?
Disease control OngoingThis study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children, adolescents, and young adults receiving a bone marrow or blood stem cell transplant for blood cancers. Researchers are first finding the best dose of vor…
Matched conditions: GRAFT VERSUS HOST DISEASE
Phase: PHASE1, PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Can a psoriasis drug stop transplant rejection?
Disease control OngoingThis phase II trial tests whether the drug ustekinumab (Stelara) can prevent acute graft-versus-host disease (GVHD) in 116 adults receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the patient's body. Ustekinumab aims to calm this immune…
Matched conditions: GRAFT VERSUS HOST DISEASE
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Could a lower dose of cyclophosphamide make stem cell transplants less risky?
Disease control OngoingThis study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can reduce side effects while still preventing the donor cells from attacking the recipient's body. The trial includes 105 people aged 15-65 with blood cancers like leukemia or…
Matched conditions: GRAFT VERSUS HOST DISEASE
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Gut bugs linked to transplant complication risk
Knowledge-focused OngoingThis study looks at how changes in gut bacteria and their byproducts after a stem cell transplant might influence the development of graft-versus-host disease (GVHD), a serious complication. Researchers will collect stool and blood samples from 88 transplant recipients and their …
Matched conditions: GRAFT VERSUS HOST DISEASE
Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC